论文部分内容阅读
目的探讨辛伐他汀对不稳定性心绞痛(UA)患者的临床意义。方法本研究入选106例UA患者,随机分为三组:常规对照组32例,给予硝酸脂类药物、阿司匹林等常规治疗;辛伐他汀A组37例,在常规治疗基础上加用辛伐他汀20mg/d;辛伐他汀B组37例,给予辛伐他汀40mg/d.;连续用药8周。分别于入院时及8周末测定血脂水平及血清CRP水平。结果:常规对照组治疗前后血脂水平差异无统计学意义(P>0.05)。辛伐他汀A、B组8周检测TC、LDL-C水平明显下降,P<0.05,B组比A组下降更显著。治疗8周后CRP水平均明显下降,有统计学意义P<0.05。辛伐他汀A组、B组与常规对照组,B组与A组相比较CRP水平下降更显著,有统计学意义P<0.05。结论辛伐他汀通过全面调脂、减轻炎症反应使UA患者受益,改善预后。
Objective To investigate the clinical significance of simvastatin in patients with unstable angina pectoris (UA). Methods A total of 106 patients with UA were enrolled in this study. They were randomly divided into three groups: conventional control group (n = 32), conventional treatment with nitric acid lipids and aspirin, and simvastatin A group (n = 37). On the basis of routine treatment, simvastatin 20mg / d; simvastatin B group 37 cases, given simvastatin 40mg / d; continuous medication for 8 weeks. Serum lipids and serum CRP levels were measured at admission and at the end of 8 weeks respectively. Results: There was no significant difference in serum lipids between before and after treatment in routine control group (P> 0.05). The levels of TC and LDL-C in Simvastatin A and B groups decreased significantly at 8 weeks (P <0.05), and decreased more significantly in B group than in A group. After 8 weeks of treatment, CRP levels were significantly decreased, with statistical significance P <0.05. Simvastatin group A, B group and conventional control group, B group and A group compared CRP level decreased more significantly, with statistical significance P <0.05. Conclusion Simvastatin can benefit patients with UA and improve prognosis through full lipid-lowering and inflammation reduction.